Ekso Bionics(TM) Completes Training at Switzerland's Largest Rehabilitation Center
July 15 2014 - 7:00AM
SPC Nottwil is Crown Jewel in Growing List of European Centers
Offering Ekso Bionics Technology
RICHMOND, Calif., July 15, 2014 (GLOBE NEWSWIRE)
-- Ekso Bionics Holdings, Inc. (OTCQB:EKSO), a robotic exoskeleton
company, announced today that SPC Nottwil has finished training
their team of physiotherapists with their Ekso GT(TM) robotic
exoskeleton for neurorehabilitation and started to book patients to
learn how to walk again. SPC Nottwil is the largest of
Switzerland's four special clinics for para and tetraplegics; they
consistently treat over 70% of all people with spinal paralysis in
Switzerland and are fully occupied all year round. They have joined
an esteemed group of European centers with an Ekso(TM) robotic
exoskeleton including the top rated Insitut Guttman in Spain and
The Clinic for Spinal Cord Injuries in Hornbaek, Denmark, now part
of Glostrup Hospital. Robotic exoskeletons have been gaining
adoption in the neurorehabilitation community as a strong and
growing body of evidence shows they are able to engage the
principles of neuroplasticity for improved patient outcomes.
"It's a huge accomplishment for us to be in these
three top rated rehabilitation hospitals in Europe," said Ekso
Bionics chief executive officer Nate Harding. "The fact that such
leading centers purchased our devices and are making our device
available to their patients is exciting - that is what I'd call
winning the 'Triple Crown' of European rehab."
Recent studies in Europe have shown a range of
potential benefits using the Ekso GT robotic exoskeleton in
neurorehabilitation. In a study at BG Hospital Bergmannstrost
Halle, measuring quality of life, patients reported their pain was
reduced from walking in an Ekso Bionics robotic exoskeleton. The
Company believes pain reduction is a particularly meaningful
benefit when one considers a possible correlating reduction of
medication and side effects. Bergmannstrost also reported a
reduction in spasticity and an overall improvement in quality of
life. All 13 subjects stated that the ability to stand and walk
over ground again had a definite positive effect in mental
wellbeing. As the study described, "To be able to approach someone
at eye level and literally be able 'to look someone in the eye'
again was often described as incredible." These results outline
some of the reasons that neurorehabilitation centers around the
world are integrating Ekso Bionics technology into their
practice.
Ekso Bionics designs, develops, and commercializes
exoskeletons, or wearable robots, which have a variety of
applications in the medical, military, industrial, and consumer
markets. Exoskeletons are ready-to-wear, battery-powered robots
that are strapped over the user's clothing, enabling individuals to
achieve mobility, strength, and endurance not otherwise possible.
Ekso Bionics' lead product, Ekso, is a wearable bionic suit that
enables individuals with any amount of lower extremity weakness to
stand up and walk over ground. It is the only robotic exoskeleton
to offer variable assist which provides varying amounts of power to
each side and makes it an optimal rehabilitation device for those
with hemiplegia. With a CE 2A classification in Europe and a class
1 FDA approval in the United States, Ekso is forging a new frontier
in rehabilitation for people living with the consequences of
stroke, spinal cord injury and other neurological conditions
affecting gait.
About Ekso
Bionics
Since 2005, Ekso Bionics has been pioneering the
field of robotic exoskeletons, or wearable robots, to augment human
strength, endurance and mobility. The company's first commercially
available product called Ekso has helped thousands of people living
with paralysis take millions of steps not otherwise possible. By
designing and creating some of the most forward-thinking and
innovative solutions for people looking to augment human
capabilities, Ekso Bionics is helping people rethink current
physical limitations and achieve the remarkable.
Ekso Bionics is headquartered in Richmond, CA and
is listed on the OTC QB under the symbol EKSO. To learn more about
Ekso Bionics please visit us at www.eksobionics.com
Facebook: www.facebook.com/eksobionics
Twitter: @eksobionics
YouTube:http://www.youtube.com/user/EksoBionics/
Forward-Looking
Statements
Any statements contained in this press release
that do not describe historical facts may constitute
forward-looking statements. Forward-looking statements may include,
without limitation, statements regarding (i) the plans and
objectives of management for future operations, including plans or
objectives relating to the design, development and
commercialization of human exoskeletons, (ii) a projection of
income (including income/loss), earnings (including earnings/loss)
per share, capital expenditures, dividends, capital structure or
other financial items, (iii) the Company's future financial
performance and (iv) the assumptions underlying or relating to any
statement described in points (i), (ii) or (iii) above. Such
forward-looking statements are not meant to predict or guarantee
actual results, performance, events or circumstances and may not be
realized because they are based upon the Company's current
projections, plans, objectives, beliefs, expectations, estimates
and assumptions and are subject to a number of risks and
uncertainties and other influences, many of which the Company has
no control over. Actual results and the timing of certain events
and circumstances may differ materially from those described by the
forward-looking statements as a result of these risks and
uncertainties. Factors that may influence or contribute to the
inaccuracy of the forward-looking statements or cause actual
results to differ materially from expected or desired results may
include, without limitation, the Company's inability to obtain
adequate financing, the significant length of time and resources
associated with the development of our products and related
insufficient cash flows and resulting illiquidity, the Company's
inability to expand the Company's business, significant government
regulation of medical devices and the healthcare industry, lack of
product diversification, volatility in the price of the Company's
raw materials, existing or increased competition, results of
arbitration and litigation, stock volatility and illiquidity, and
the Company's failure to implement the Company's business plans or
strategies. These and other factors are identified and described in
more detail in the Company's filings with the SEC, including, the
Company's Current Report on Form 8-K filed on March 31, 2014 and
the Company's latest Form 10-Q filed on May 13, 2014. The Company
does not undertake to update these forward-looking statements.
CONTACT: Media Contact:
Heidi Darling, Marketing Manager
Phone: 415.302.4777
hdarling@eksobionics.com
Investor Contact:
Lauren Glaser, Vice President
Phone: 646.378.2972
lglaser@troutgroup.com
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Ekso Bionics via Globenewswire
HUG#1824990
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Sep 2023 to Sep 2024